IQVIA Holdings Inc. $IQV Shares Sold by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 34.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,723 shares of the medical research company’s stock after selling 4,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in IQVIA were worth $1,317,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Morningstar Investment Management LLC increased its holdings in shares of IQVIA by 4.9% in the 1st quarter. Morningstar Investment Management LLC now owns 19,341 shares of the medical research company’s stock valued at $3,298,000 after purchasing an additional 897 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in IQVIA by 3.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 992,190 shares of the medical research company’s stock worth $169,208,000 after buying an additional 30,051 shares in the last quarter. Liberty One Investment Management LLC grew its position in IQVIA by 11.1% during the first quarter. Liberty One Investment Management LLC now owns 3,219 shares of the medical research company’s stock worth $549,000 after buying an additional 322 shares during the period. Sei Investments Co. increased its holdings in IQVIA by 7.3% in the first quarter. Sei Investments Co. now owns 130,461 shares of the medical research company’s stock valued at $22,248,000 after buying an additional 8,925 shares in the last quarter. Finally, Lido Advisors LLC increased its holdings in IQVIA by 7.5% in the first quarter. Lido Advisors LLC now owns 5,074 shares of the medical research company’s stock valued at $865,000 after buying an additional 353 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

NYSE:IQV opened at $208.22 on Monday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $247.04. The firm has a market cap of $34.75 billion, a price-to-earnings ratio of 25.80, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. The company’s 50-day moving average is $188.23 and its two-hundred day moving average is $187.05. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

IQV has been the topic of several research analyst reports. HSBC reissued a “buy” rating and set a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Mizuho boosted their target price on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.